Transcenta Holding Ltd
Company Profile
Business description
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, manufacturing, and business development. It is developing approximately fifteen therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders. The company's drug development pipeline includes Osemitamab (TST001), TST002 (Blosozumab), TST003, TST006, MSB2311, MSB0254, TST808, and others to treat various oncology and non-oncology complications in different ways. Geographically, the company operates in China (the PRC), which is its key revenue market, and the United States of America.
Contact
218 Xinghu Street
B6-501, Biobay
Suzhou215123
CHNT: +86 51267079200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
200
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,586.70 | 15.30 | 0.18% |
| CAC 40 | 7,734.40 | 130.04 | -1.65% |
| DAX 40 | 23,629.58 | 369.59 | -1.54% |
| Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
| FTSE 100 | 8,717.97 | 21.29 | -0.24% |
| HKSE | 23,601.26 | 56.95 | 0.24% |
| NASDAQ | 18,737.21 | 188.53 | -1.00% |
| Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
| NZX 50 Index | 12,596.50 | 65.75 | -0.52% |
| S&P 500 | 5,802.82 | 39.19 | -0.67% |
| S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
| SSE Composite Index | 3,348.37 | 31.82 | -0.94% |